RVO Publications

Initial response and 12-month outcomes after commencing dexamethasone or vascular endothelial growth factor inhibitors for retinal vein occlusion in the FRB registry

Scientific Reports

, (epub)

March 2024

Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry

British Journal of Ophthalmology

June 2023

Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion

Eye

April 2023

One-year real-world outcomes of bevacizumab for the treatment of macular oedema secondary to retinal vein occlusion

Clinical and Experimental Ophthalmology

December 2022

Central retinal vein occlusion 36-month outcomes with anti-vascular endothelial growth factors: the Fight Retinal Blindness! registry

Ophthalmol Retina

November 2022

Incidence, Risk Factors and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor for Retinal Diseases: Data from the Fight Retinal Blindness! Registry

Ophthalmology Retina

November 2022

Twelve-month treatment outcomes of macular edema following central retinal vein occlusion using aflibercept or ranibizumab in routine clinical practice – data from the Fight Retinal Blindness! project

Acta Ophthalmologica

June 2022

12-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry

British Journal of Ophthalmology

June 2022

Quality of life impact of eye diseases: a Save Sight Registries study

Clinical and Experimental Ophthalmology

May 2022

International impact of the COVID-19 pandemic lockdown on intravitreal therapy outcomes: Fight Retinal Blindness registry

Retina

April 2022

Email: ssi.ssr@sydney.edu.au
Phone: (+61) 421 787 808

Level 1, South Block
Sydney Eye Hospital
8 Macquarie Street
Sydney NSW 2000

Follow us

Quick links